741 Modulating immune responses to therapeutic cancer vaccines using precision delivery technologies

<h3>Background</h3> PharmaJet Precision Delivery Systems (PDS) are needle-free injection devices that are leading a transformation on how cancer immunotherapeutics harness the full power of the immune system. <h3>Methods</h3> The Tropis® intradermal PDS has been shown to better activate the immune system through more efficient delivery of vaccines into the dermis where diverse populations of antigen-presenting cells (APC) reside. The Stratis® intramuscular PDS is extensively used in clinical trials for therapeutic DNA vaccines. <h3>Results</h3> Published data show a robust induction of tumor-specific and durable cellular immune responses that lead to better clinical outcomes for multiple cancer types, including tumor size regression and increased survivability, compared to traditional delivery methods like needle and syringe. Through these results, PharmaJet PDS have enabled late-stage clinical development of multiple APC-targeting therapeutic vaccines, including regimens where vaccination is combined with check-point inhibitor administration. The talk will review the main characteristics and clinical results of various therapeutic cancer vaccines administered using our proprietary delivery technologies. <h3>Conclusions</h3> PharmaJet PDS are commercial, validated delivery systems with established manufacturing, safety, and efficacy profiles for injection of various vaccines and therapeutics. Additionally, the PDS are particularly well suited to improving vaccination programs due to their portability, ease of use, cost-effectiveness, and acceptability by users and patients.